Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.46 |
| ▸ | RAD52 | P43351 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 3/20 | 0.42 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ACHE | P22303 | 9/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3908462 | 0.93 | NAAA (0.52) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL18679878 | 0.93 | NAAA (0.52) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL28284649 | 0.93 | NAAA (0.52) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1499895 | 0.93 | NAAA (0.52) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL1537692 | 0.93 | NAAA (0.52) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL19367023 | 0.93 | NAAA (0.52) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL19367026 | 0.88 | NAAA (0.41) | NAAARAD52NPSR1EPHX1TSHR | |
| SCHEMBL13635968 | 0.86 | HCAR2 (0.33) | TSHRHCAR2ALDH1A1LMNA | |
| SCHEMBL15334588 | 0.86 | HCAR2 (0.33) | TSHRHCAR2ALDH1A1LMNA | |
| SCHEMBL8384168 | 0.86 | ALDH1A1 (0.50) | NAAAEPHX1TSHRHCAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2017-03-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170087167-A1 | MODIFICATION OF DRUGS FOR INCORPORATION INTO NANOPARTICLES | NLN, PRNP, TPMT | NAAA 110/4885RAD52 4855/4885NPSR1 512/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.